Hypertrophic cardiomyopathy risk factors for sudden death: Difference between revisions
| Line 17: | Line 17: | ||
*[[Bradyarrhythmias]] (slow rhythms of the heart). | *[[Bradyarrhythmias]] (slow rhythms of the heart). | ||
==2011 ACCF/AHA Guideline Recommendations: SCD Risk Stratification (DO NOT EDIT)== | == 2011 ACCF/AHA Guideline Recommendations: SCD Risk Stratification (DO NOT EDIT) == | ||
{{cquote| | {{cquote| | ||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]=== | === [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] === | ||
'''1.''' All patients with HCM should undergo comprehensive SCD risk stratification at initial evaluation to determine the presence of the following: | '''1.''' All patients with HCM should undergo comprehensive SCD risk stratification at initial evaluation to determine the presence of the following: | ||
a. A personal history for ventricular fibrillation, sustained VT, or SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias. | a. A personal history for ventricular fibrillation, sustained VT, or SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias. | ||
b. A family history for SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias. | b. A family history for SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias. | ||
c. Unexplained syncope. | c. Unexplained syncope. | ||
d. Documented NSVT defined as 3 or more beats at greater than or equal to 120 bpm on ambulatory (Holter) ECG. | d. Documented NSVT defined as 3 or more beats at greater than or equal to 120 bpm on ambulatory (Holter) ECG. | ||
e. Maximal LV wall thickness greater than or equal to 30 mm. | e. Maximal LV wall thickness greater than or equal to 30 mm. | ||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]=== | |||
=== [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] === | |||
([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) | ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) | ||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]=== | === [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] === | ||
}} | }} | ||
Revision as of 20:06, 1 October 2012
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy risk factors for sudden death On the Web |
|
FDA on Hypertrophic cardiomyopathy risk factors for sudden death |
|
CDC on Hypertrophic cardiomyopathy risk factors for sudden death |
|
Hypertrophic cardiomyopathy risk factors for sudden death in the news |
|
Blogs on Hypertrophic cardiomyopathy risk factors for sudden death |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy risk factors for sudden death |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Patients with hypertrophic cardiomyopathy are increased risk of sudden cardiac death. Identification of those patients at an increased risk can facilitate early treatment with an automatic implantable cardiac defibrillator.
Risk Factors for Sudden Death in Patients with Hypertrophic Cardiomyopathy
Risk factors for sudden death in individuals with HCM include[1]:
- A young age at first diagnosis (age < 30 years)
- An episode of aborted sudden death
- A family history of HCM with sudden death of relatives
- Specific mutations in the genes encoding for troponin T and myosin
- Sustained supraventricular or ventricular tachycardia
- Ventricular septal wall thickness over 3 cm
- A hypotensive response to exercise
- Recurrent syncope (especially in children)
- Bradyarrhythmias (slow rhythms of the heart).
2011 ACCF/AHA Guideline Recommendations: SCD Risk Stratification (DO NOT EDIT)
| “ |
Class I1. All patients with HCM should undergo comprehensive SCD risk stratification at initial evaluation to determine the presence of the following: a. A personal history for ventricular fibrillation, sustained VT, or SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias. b. A family history for SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias. c. Unexplained syncope. d. Documented NSVT defined as 3 or more beats at greater than or equal to 120 bpm on ambulatory (Holter) ECG. e. Maximal LV wall thickness greater than or equal to 30 mm.
Class IIaClass IIb |
” |
References
- ↑ Maron BJ, Cecchi F, McKenna WJ (1994). "Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy". Br Heart J. 72 (6 Suppl): S13–8. doi:10.1136/hrt.72.6_Suppl.S13. PMC 1025670. PMID 7873317. Unknown parameter
|month=ignored (help) and the Task Force on Sudden Cardiac Death of the European Society of Cardiology link Note: Guideline withdraw